학술논문
Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives
Document Type
article
Author
Alessandro Ottaiano; Mariachiara Santorsola; Luisa Circelli; Anna Maria Trotta; Francesco Izzo; Francesco Perri; Marco Cascella; Francesco Sabbatino; Vincenza Granata; Marco Correra; Luca Tarotto; Salvatore Stilo; Francesco Fiore; Nicola Martucci; Antonello La Rocca; Carmine Picone; Paolo Muto; Valentina Borzillo; Andrea Belli; Renato Patrone; Edoardo Mercadante; Fabiana Tatangelo; Gerardo Ferrara; Annabella Di Mauro; Giosué Scognamiglio; Massimiliano Berretta; Maurizio Capuozzo; Angela Lombardi; Jérôme Galon; Oreste Gualillo; Ugo Pace; Paolo Delrio; Giovanni Savarese; Stefania Scala; Guglielmo Nasti; Michele Caraglia
Source
Cancers, Vol 15, Iss 6, p 1827 (2023)
Subject
Language
English
ISSN
2072-6694
Abstract
Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers, as well as methodological challenges and perspectives characterizing OMD. Recent studies have revealed that specific microRNA profiles, chromosome patterns, driver gene mutations (ERBB2, PBRM1, SETD2, KRAS, PIK3CA, SMAD4), polymorphisms (TCF7L2), and levels of immune cell infiltration into metastases, depending on the tumor type, are associated with an oligometastatic behavior. This suggests that OMD could be a distinct disease with specific biological and molecular characteristics. Therefore, the heterogeneity of initial tumor burden and inclusion of OMD patients in clinical trials pose a crucial methodological question that requires responses in the near future. Additionally, a solid understanding of the molecular and biological features of OMD will be necessary to support and complete the clinical staging systems, enabling a better distinction of metastatic behavior and tailored treatments.